The new 2018 guideline, published in the official journal of the College of Family Physicians of Canada, suggests that clinicians could consider medical cannabinoids only for refractory neuropathic pain and refractory pain in palliative care, chemotherapy-induced nausea and vomiting, and spasticity in multiple sclerosis and spinal cord injury after reasonable trials of standard therapies have failed.
Medical cannabis found to reduce chronic pain in older patients 65+: Multiple Sclerosis News Today
Medical cannabis was found to safely and significantly reduce chronic pain in older patients with multiple sclerosis (MS) and a wide range of other conditions, researchers in Israel report. Full article with link to research here.